PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.						
	Substitute for form 1449B/PTO				Complete if Known	PE
	INFORMATIO	N DISCLO	SURE	Application Number	09/120,383	70, 31
	STATEMENT	BY APPLI	CANT	Filing Date	July 22, 1998	7
	Data Cubmittadi	Echanon (24 2002	First Named Inventor	Fumihiko WANTANABE	FEB 2 1 2000
	Date Submitted:	rebluary 2	21, 2003	Group Art Unit	1621	T K
	(use as many sh	eets as ne	cessary)	Examiner Name	S. Barts	3.
Sheet	1	of	2	Attorney Docket Number	067242-0107	TA TRADE

				U.S. PATENT DOCUMENTS	8	
	Cite No. ¹	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
5/3	B1	3,784,701		Tomcufcik et al.	01/08/1974	
771	B2	4,269,775		Szczepanski et al.	05/26/1981	
	B3	4,388,464		Kristinsson et al.	06/14/1983	Α.
	B4	4,599,361		Dickens et al.	07/08/1986	1/20
	B5	4,632,931		Nakane	12/30/1986	`````
	B6	4,715,883		Lukaszczyk et al.	12/29/1987	Fo
	B7	5,270,326		Galardy et al.	12/14/1993	
1	B8	6,150,394		Watanabe et al.	11/21/2000	40 5
7	B9	5,854,277		Kluender et al.	12/29/1998	CFA12 <002
7	B10	6,207,698	B1	Wantanabe et al.	03/27/2001	VIED
7.	B11	6,441,021	B1	Wantanabe et al.	08/27/2002	7/60
517	B12	6,235,768	B1	Wantanabe et al.	05/22/2001	00/20
<i></i>						~50n

			-		FOREIGN PATENT DOCUMENTS)		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Office ³ Number ⁴ Code ⁵ (if known)		Kind Code ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
5/1	B13	EP	0 305 947	A1	Mochida Pharmaceutical Co., Ltd.	03/08/1989		
	B14	EP	0 548 798	A1	Sanwa Kagaku Kenkyusho Co., Ltd.	06/30/1993		
18	B15	EP	0 606 046	B1	MacPherson et al.	07/13/1994		
7	B16	WO	94/12181	A1	Merck & Co. Inc.	06/09/1994		
1	B17	WO	95/13289	A1	Chiroscience Limited	05/18/1995		}
	B18	wo	95/35275	A1	British Biotech Pharmaceuticals Limited	12/28/1995		
	B19	WO	96/11209	A1	Chiroscience Limited	04/18/1996		
(n)	B20	WO	96/15096	A1	Bayer Corporation	05/23/1996		
5/1/2	B21	wo	97/27174	A1	Shionogi & Co., Ltd.	07/31/1997		

Examiner Signature	Date Considered	11/4/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

^{*}EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO INFORMATION DISCLOSURE					Complete if Known	(10)
				Application Number	09/120,383	10.6
	STATEMENT BY A	APPLIC	CANT	Filing Date	July 22, 1998	7
	Data Cubmittadi Eabi		1 2002	First Named Inventor	Fumihiko WANTANABE	14210
	Date Submitted: Febr	luary 2	1, 2003	Group Art Unit	1621	100
	(use as many sheets	as nec	cessary)	Examiner Name	S. Barts	
Sheet	2	of	2	Attorney Docket Number	067242-0107	RADBAS

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶						
311	B22	Qi-Zhuang YE et al., Purification and Characterization of the Human Stromelysin Catalytic Domain Expressed in Escherichia coli, Biochemistry, September 3, 1992, pages 11231-11235, Vol. 31-Issue No. 45, American Chemical Society.							
1/2	B23	Kevin T. CHAPMAN et al., Inhibition of Matrix Metalloproteinases by N-Carboxyalkyl Peptides, Journal of Medicinal Chemistry, April 26, 1993, pages 4293-4301, Vol. 36-Issue No. 26, American Chemical Society.							

The CENTER 1600 200

Examiner Signature	3-6	Date Considered	4/4/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.